Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.32 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Benzoic Acid SCHEMBL29120392 | 0.83 | TSHR (0.42) | ALDH1A1MAPTPOLBPKMTSHR | |
| SCHEMBL10591064 | 0.78 | — | — | |
| SCHEMBL15686693 | 0.75 | GABRA1 (0.40) | ALDH1A1CYP1A2CA1CA2TSHR | |
| SCHEMBL4615662 | 0.74 | F9 (0.30) | — | |
| SCHEMBL16369633 | 0.74 | SMN1; SMN2 (0.46) | ALDH1A1MAPTPOLBPKMGAA | |
| SCHEMBL23039753 | 0.74 | LMNA (0.46) | ALDH1A1MAPTPKMGAACYP1A2 | |
| SCHEMBL346282 | 0.74 | — | — | |
| SCHEMBL289345 | 0.74 | — | — | |
| SCHEMBL313921 | 0.74 | KDM4E (0.41) | ALDH1A1MAPTPOLBGAATSHR | |
| SCHEMBL2211928 | 0.74 | PDPK1 (0.46) | ALDH1A1MAPTGAACYP1A2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2427451-B1 | ALPHA HELIX MIMETICS AND METHODS RELATING THERETO | PRISM BIOLAB CO LTD (JP) | 2019-03-20 | — | — | EP | disclosed |
| US-20180305373-A1 | ALPHA HELIX MIMETICS AND METHODS RELATING THERETO | Prism BioLab Co., Ltd. (JP) | 2018-10-25 | — | — | US | disclosed |
| US-10017522-B2 | Alpha helix mimetics and methods relating thereto | Prism BioLab Co., Ltd. (JP) | 2018-07-10 | — | — | US | disclosed |
| US-20170365791-A1 | HETEROAROMATIC COMPOUNDS FOR ORGANIC ELECTRONICS | BASF SE (DE) | 2017-12-21 | — | — | US | disclosed |
| US-9716237-B2 | Heteroacenes for organic electronics | BASF SE (DE) | 2017-07-25 | — | — | US | disclosed |
| US-9682996-B2 | Alpha helix mimetic compositions for treating cancer and other CBP/catenin-mediated diseases and conditions | Prism BioLab Co., Ltd. (JP) | 2017-06-20 | — | — | US | disclosed |
| US-20160365519-A1 | HETEROACENES FOR ORGANIC ELECTRONICS | BASF SE (DE) | 2016-12-15 | — | — | US | disclosed |
| US-9469654-B2 | Bicyclic oxa-lactam kinase inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2016-10-18 | — | — | US | disclosed |
| US-20150376204-A1 | ALPHA HELIX MIMETIC COMPOSITIONS FOR TREATING CANCER AND OTHER CBP/CATENIN-MEDIATED DISEASES AND CONDITIONS | Prism BioLab Co., Ltd. (JP) | 2015-12-31 | — | — | US | disclosed |
| US-20150368262-A1 | ALPHA HELIX MIMETICS AND METHODS RELATING THERETO | Prism BioLab Co., Ltd. (JP) | 2015-12-24 | — | — | US | disclosed |
| US-20140113931-A1 | SUBSTITUTED PICOLINAMIDE KINASE INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2014-04-24 | — | — | US | disclosed |
| US-20120088770-A1 | ALPHA HELIX MIMETICS AND METHODS RELATING THERETO | PRISM BIOLAB CORPORATION (JP) | 2012-04-12 | — | — | US | disclosed |
| EP-2427451-A1 | ALPHA HELIX MIMETICS AND METHODS RELATING THERETO | PRISM BioLab Corporation (JP) | 2012-03-14 | — | — | EP | disclosed |
| US-20110263607-A1 | ALPHA HELIX MIMETICS IN THE TREATMENT OF CANCER | PRISM BIOLAB CORPORATION (JP) | 2011-10-27 | — | — | US | disclosed |
| EP-2346871-A1 | ALPHA HELIX MIMETICS IN THE TREATMENT OF CANCER | PRISM BioLab Corporation (JP) | 2011-07-27 | — | — | EP | disclosed |
| WO-2010128685-A1 | ALPHA HELIX MIMETICS AND METHODS RELATING THERETO | PRISM BIOLAB CORPORATION (JP) | 2010-11-11 | — | — | WO | disclosed |
| WO-2010044485-A1 | ALPHA HELIX MIMETICS IN THE TREATMENT OF CANCER | PRISM BIOLAB CORPORATION (JP) | 2010-04-22 | — | — | WO | disclosed |
| WO-1998025888-A1 | PROCESS FOR PREPARING ISOCYANATES FROM PRIMARY AMINES WHICH ARE NOT READILY DISSOLVED | BAYER AKTIENGESELLSCHAFT (DE) | 1998-06-18 | — | — | WO | disclosed |
| EP-0420803-A2 | Benzo-1,2,3-thiadiazole derivatives and their use for protecting plants against diseases | CIBA-GEIGY AG (CH) | 1991-04-03 | — | — | EP | disclosed |
| EP-0347377-A2 | 1,2,3-Benzothiadiazole-4-carboxylic-acid derivatives as plant growth regulators | CIBA-GEIGY AG (CH) | 1989-12-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160365519-A1 | HETEROACENES FOR ORGANIC ELECTRONICS | YBX1, PIEZO1, HAX1 | ALDH1A1 560/4885MAPT 3858/4885BRPF1 2418/4885 |
| US-20150368262-A1 | ALPHA HELIX MIMETICS AND METHODS RELATING THERETO | PLOD3, COL1A1, THPO | ALDH1A1 1511/4885MAPT 1638/4885BRPF1 2666/4885 |
| US-20120088770-A1 | ALPHA HELIX MIMETICS AND METHODS RELATING THERETO | PLOD3, COL1A1, THPO | ALDH1A1 1511/4885MAPT 1638/4885BRPF1 2666/4885 |
| US-20170365791-A1 | HETEROAROMATIC COMPOUNDS FOR ORGANIC ELECTRONICS | OR10J3, NR0B1, NR0B2 | ALDH1A1 1283/4885MAPT 4373/4885BRPF1 2256/4885 |
| US-20140113931-A1 | SUBSTITUTED PICOLINAMIDE KINASE INHIBITORS | SYK, LCK, BTK | ALDH1A1 4736/4885MAPT 2085/4885BRPF1 1285/4885 |
| US-20180305373-A1 | ALPHA HELIX MIMETICS AND METHODS RELATING THERETO | PLOD3, COL1A1, THPO | ALDH1A1 1511/4885MAPT 1638/4885BRPF1 2666/4885 |
| US-20110263607-A1 | ALPHA HELIX MIMETICS IN THE TREATMENT OF CANCER | COL1A1, HDGF, HCCS | ALDH1A1 1264/4885MAPT 2160/4885BRPF1 2192/4885 |
| US-10017522-B2 | Alpha helix mimetics and methods relating thereto | PLOD3, COL1A1, THPO | ALDH1A1 1511/4885MAPT 1638/4885BRPF1 2666/4885 |
| US-20150376204-A1 | ALPHA HELIX MIMETIC COMPOSITIONS FOR TREATING CANCER AND OTHER CBP/CATENIN-MEDIATED DISEASES AND CONDITIONS | CREBBP, CTNNB1, CTNNA1 | ALDH1A1 2753/4885MAPT 2270/4885BRPF1 541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.